(+)-PD 128907 hydrochloride

Pricing Availability   Qty
Cat.No. 1243 - (+)-PD 128907 hydrochloride | C14H19NO3.HCl | CAS No. 300576-59-4
Description: High affinity D3 agonist (D3 ≥ D2 > D4)
Chemical Name: (4aR,10bR)-3,4a,4,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol hydrochloride
Purity: ≥98% (HPLC)
Citations (9)
Literature (5)

Biological Activity

High affinity D3 dopamine receptor agonist (Ki = 2.3 nM). Displays 18 - 200-fold selectivity over other dopamine receptor subtypes.

Technical Data

M. Wt 285.77
Formula C14H19NO3.HCl
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 300576-59-4
PubChem ID 11957668
Smiles CCCN3[C@@H]2COC1=CC=C(O)C=C1[C@H]2OCC3.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
water 2.86 10

Preparing Stock Solutions

The following data is based on the product molecular weight 285.77. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 34.99 mL 174.97 mL 349.93 mL
0.5 mM 7 mL 34.99 mL 69.99 mL
1 mM 3.5 mL 17.5 mL 34.99 mL
5 mM 0.7 mL 3.5 mL 7 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:


References are publications that support the biological activity of the product.

Bristow et al (1996) The behavioural and neurochemical profile of the putative DA D3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology 35 285 PMID: 8783203

Pugsley et al (1995) Neurochemical and functional characterization of the preferentially selective DA D3 agonist PD 128907. J.Pharmacol.Exp.Ther. 275 1355 PMID: 8531103

Witkin et al (1998) Atypical antipsychotic-like effects of the DA D3 receptor agonist (+)-PD 128907. Eur.J.Pharmacol. 347 R1 PMID: 9741997

If you know of a relevant reference for (+)-PD 128907 hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all D3 Receptor Agonists

Keywords: (+)-PD 128907 hydrochloride, (+)-PD 128907 hydrochloride supplier, D3, agonists, D2, D4, Dopamine, Receptors, dopaminergic, (+)-PD128907, hydrochloride, PD128907, 1243, Tocris Bioscience

9 Citations for (+)-PD 128907 hydrochloride

Citations are publications that use Tocris products. Selected citations for (+)-PD 128907 hydrochloride include:

Schulz et al (2012) First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol 167 1480 PMID: 22817643

Basso et al (2005) Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 30 1257 PMID: 15688083

Zhang et al (2004) Cocaine-induced intracellular signaling and gene expression are oppositely regulated by the DA D1 and D3 receptors. J Neurosci 24 3344 PMID: 15056714

Clemens and Hochman (2004) Conversion of the modulatory actions of DA on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24 11337 PMID: 15601940

Do you know of a great paper that uses (+)-PD 128907 hydrochloride from Tocris? Please let us know.

Reviews for (+)-PD 128907 hydrochloride

There are currently no reviews for this product. Be the first to review (+)-PD 128907 hydrochloride and earn rewards!

Have you used (+)-PD 128907 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.


Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.